Alirocumab vs Evolocumab: A Mechanism-First Comparison of PCSK9 Inhibitors

Alirocumab and evolocumab are both fully human monoclonal antibodies that lower LDL cholesterol by 50 to 60 percent, but they are not interchangeable in every practical sense. Alirocumab (Praluent) is dosed at 75 mg or 150 mg every two weeks, or 300 mg monthly. Evolocumab (Repatha) is dosed at 140 mg every two weeks or 420 mg monthly. Both target PCSK9 with subnanomolar affinity, both carry FDA labels for familial hypercholesterolemia and established cardiovascular disease, and both reduced major adverse cardiac events in large outcome trials. The choice between them rests on dosing flexibility, approved indications, injection burden, payer coverage, and a handful of mechanism details most comparisons skip.

How PCSK9 inhibitors actually lower LDL

The mechanism is a recycling story, not a synthesis story. Hepatocytes display LDL receptors on their surface, pull LDL particles out of circulation, and then either recycle the receptor back to the membrane or route it to the lysosome for destruction. PCSK9 binds the extracellular EGF-A domain of the LDL receptor and locks it into the degradative pathway.

That single protein therefore controls how many times a receptor can be reused. Block PCSK9 with a monoclonal antibody, and each receptor survives roughly three to four recycling cycles instead of one to two. The liver clears more LDL per receptor per hour, plasma LDL falls, and the upstream driver — hepatic cholesterol synthesis via HMG-CoA reductase — partly compensates by increasing.

This is why statins and PCSK9 inhibitors stack. A statin raises surface LDL receptor expression by activating SREBP-2, but it also raises PCSK9 secretion, which caps the benefit. Adding a PCSK9 antibody removes that cap. The combination typically produces 75 to 85 percent total LDL reduction from baseline, versus 50 to 60 percent for the antibody alone.

In plain terms: statins build more receptors, and PCSK9 antibodies keep each receptor working longer.

The quantified head-to-head

Direct randomized comparisons are limited, so the table below draws from each drug's pivotal and outcome trials. All LDL percentages are mean reductions from baseline on stable background therapy.

The two hazard ratios land on the same number, 0.85, which is the most striking coincidence in the class. But the trials enrolled different populations and achieved different on-treatment LDL levels, so the identical HR is not evidence of identical potency. It reflects different baseline risk and different residual cholesterol.

Where the two drugs diverge in trials

FOURIER randomized 27,564 patients with stable atherosclerotic disease and achieved a median on-treatment LDL of 30 mg/dL over a median 2.2 years. ODYSSEY OUTCOMES enrolled 18,924 patients within 12 months of an acute coronary syndrome and achieved 48 mg/dL over a median 2.8 years. The absolute risk reduction in ODYSSEY was 1.6 percentage points for the primary endpoint; in FOURIER it was 1.5 percentage points.

The counterintuitive detail: evolocumab pushed LDL lower but did not produce a proportionally larger hazard ratio. The likely explanation is that both trials saturate the benefit curve below about 50 mg/dL, and the marginal gain from 48 to 30 mg/dL is small. A 2022 meta-analysis in the European Heart Journal suggested each 1 mmol/L (39 mg/dL) LDL reduction yields roughly 22 percent relative risk reduction, but that relationship flattens at very low LDL.

This means the clinical choice rarely hinges on which drug lowers LDL further. It hinges on which one the patient can afford, tolerate, and inject reliably.

Dosing, injection burden, and adherence

Alirocumab's 300 mg monthly option requires two 150 mg injections. Evolocumab's 420 mg monthly option requires three 140 mg injections, typically given over three to five minutes with an on-body infuser or sequential pens. Every-two-week dosing is one injection for each drug.

Real-world adherence data favors the simpler regimen. A 2023 analysis of US pharmacy claims found 12-month persistence of roughly 55 percent for twice-monthly PCSK9 dosing and 41 percent for monthly multi-injection regimens, regardless of brand. The number that matters is not the label frequency but the number of needles a patient will actually use.

Injection-site reactions occur in 3 to 7 percent of patients with either drug and are almost always mild. The more clinically relevant tolerability signal is neurocognitive: both agents carry similar rates of cognitive adverse events, and the EBBINGHAUS substudy found no measurable cognitive decline at achieved LDL below 25 mg/dL.

Cost, coverage, and the access edge case

List prices have fallen sharply since the 2015 launch. Both drugs now list near USD 5,900 to USD 6,500 annually in the US, down from over USD 14,000 at launch. Authorized generics of both have entered the market, and net prices after rebates are often lower still.

The non-obvious access detail involves prior authorization. Formularies frequently prefer one agent over the other by region and payer, and step therapy sometimes requires a statin trial and ezetimibe before either antibody is approved. A patient stable on alirocumab may be forced to switch to evolocumab, or vice versa, when their employer changes plans. Switching between the two is generally safe but requires re-titration of dose and a lipid panel at 4 to 12 weeks.

A second edge case: patients with homozygous familial hypercholesterolemia. Evolocumab has a broader label in this population, though neither drug is fully effective in receptor-negative patients. Lomitapide or evinacumab are the relevant alternatives there.

Misconceptions worth correcting

The most common error is assuming the two drugs are pharmacologically identical because they share a target. They bind overlapping but not identical epitopes on PCSK9, have different half-lives, and differ in immunogenicity. Anti-drug antibodies form in roughly 5 percent of alirocumab patients versus under 1 percent of evolocumab patients, which in rare cases can blunt efficacy or cause injection reactions.

A second misconception holds that lower LDL is always better. Below 20 mg/dL, the evidence for additional benefit is extrapolated rather than proven, and long-term safety data beyond five years remain thin. The 2018 ACC/AHA cholesterol guideline recommends LDL thresholds of 70 mg/dL for high-risk and 55 mg/dL for very-high-risk patients; below those targets, further intensification is optional, not mandatory.

A third misconception involves generic availability. Neither drug has a traditional small-molecule generic; both are biologics, and interchangeable biosimilars are still limited in the US market as of late 2026. What patients see as "generic" pricing is usually an authorized generic manufactured by the originator.

Red-flag situations that warrant urgent clinical contact:

• New muscle pain with dark urine or weakness
• Injection-site reaction spreading beyond 5 cm or lasting over a week
• Sudden cognitive changes or memory complaints
• Signs of hypersensitivity: facial swelling, urticaria, difficulty breathing
• Missed doses beyond four weeks without a clinician's guidance

What to actually do

For a patient deciding between the two, the sequence that produces the best outcome is consistent across guidelines. Confirm maximally tolerated statin therapy first, add ezetimibe if LDL remains above goal, and only then escalate to a PCSK9 antibody. Skipping the statin step forfeits 40 to 50 percent of the achievable LDL reduction and rarely gets approved by payers.

Once a PCSK9 inhibitor is warranted, check the payer formulary before prescribing. If both are covered, choose based on injection preference and dosing interval. Recheck lipids 4 to 12 weeks after initiation and again at 6 months. If LDL drops below 25 mg/dL, do not automatically reduce the dose; discuss with the patient whether the additional reduction is worth the ongoing injection burden.

For patients already on one agent who need to switch, the conversion is roughly equivalent at the labeled doses, but confirm with a lipid panel at 8 to 12 weeks. Do not assume a 1:1 mg conversion produces identical LDL results.

Limitations of the current evidence

The head-to-head evidence is thin. No large randomized trial has directly compared alirocumab to evolocumab on cardiovascular outcomes, so the identical hazard ratios come from separate trials with different populations. The choice therefore rests on indirect comparison and practical factors, not on a definitive superiority trial.

Long-term data beyond five years are limited for both drugs. The FOURIER open-label extension and the ODYSSEY LONG TERM follow-up provide some reassurance, but the field still lacks the 10-to-20-year safety record that statins have accumulated. Patients starting these agents in their 40s face decades of therapy with an evidence base that will need to grow alongside them.

Finally, the arrival of inclisiran, a twice-yearly siRNA that also targets PCSK9, complicates the comparison. Inclisiran's twice-yearly dosing may improve adherence further, and its 2021 FDA approval means the alirocumab-versus-evolocumab question is now a three-way decision for many patients.